The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 99.90M | 98.58M | 94.67M | 85.79M | 82.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 99.90M | 98.58M | 94.67M | 85.79M | 82.04M |
| Cost of Revenue | 85.54M | 85.55M | 82.70M | 71.41M | 66.06M |
| Gross Profit | 14.37M | 13.03M | 11.97M | 14.38M | 15.98M |
| SG&A Expenses | 26.65M | 27.87M | 28.45M | 28.20M | 28.16M |
| Depreciation & Amortization | 1.57M | 1.52M | 1.49M | 1.58M | 1.70M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 113.75M | 114.94M | 112.64M | 101.19M | 95.92M |
| Operating Income | -13.85M | -16.36M | -17.97M | -15.40M | -13.88M |
| Income Before Tax | -16.11M | -15.48M | -19.89M | -19.07M | -17.28M |
| Income Tax Expenses | -- | -- | -- | -314.00K | 135.00K |
| Earnings from Continuing Operations | -16.11M | -15.48M | -19.89M | -18.75M | -17.42M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.11M | -15.48M | -19.89M | -18.75M | -17.42M |
| EBIT | -13.85M | -16.36M | -17.97M | -15.40M | -13.88M |
| EBITDA | -12.28M | -14.85M | -16.48M | -13.82M | -12.19M |
| EPS Basic | -0.18 | -0.17 | -0.22 | -0.21 | -0.19 |
| Normalized Basic EPS | -0.13 | -0.13 | -0.17 | -0.17 | -0.14 |
| EPS Diluted | -0.18 | -0.17 | -0.22 | -0.21 | -0.19 |
| Normalized Diluted EPS | -0.13 | -0.13 | -0.17 | -0.17 | -0.14 |
| Average Basic Shares Outstanding | 75.52M | 74.75M | 74.23M | 73.47M | 73.47M |
| Average Diluted Shares Outstanding | 75.52M | 74.75M | 74.23M | 73.47M | 73.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
